Invention Grant
- Patent Title: Fused Tricyclic Compounds as novel mTOR inhibitors
- Patent Title (中): 融合的三环化合物作为新的mTOR抑制剂
-
Application No.: US13379685Application Date: 2010-06-30
-
Publication No.: US08609675B2Publication Date: 2013-12-17
- Inventor: Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui
- Applicant: Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Li Su; Laura M. Ginkel
- International Application: PCT/US2010/040604 WO 20100630
- International Announcement: WO2011/002887 WO 20110106
- Main IPC: A01N43/54
- IPC: A01N43/54 ; C07D491/00
Abstract:
The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.
Public/Granted literature
- US20120178744A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS Public/Granted day:2012-07-12
Information query
IPC分类:
